SCHEMBL31161114

SCHEMBL31161114

COc1cccc2[nH]c(=O)n(C(C)C(=O)O)c(=O)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 1/20 0.44
▸ ALDH1A1 P00352 8/20 0.41
▸ KDM4E B2RXH2 7/20 0.41
▸ MAPT P10636 4/20 0.41
▸ HPGD P15428 4/20 0.41
▸ MAPKAPK2 P49137 1/20 0.40
▸ KMT2A Q03164 5/20 0.38
▸ POLB P06746 4/20 0.38
▸ DAO P14920 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ KCNA5 P22460 1/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ GAA P10253 3/20 0.38
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ RECQL P46063 2/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ FEN1 P39748 1/20 0.37
▸ RCE1 Q9Y256 1/20 0.37
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31161062 0.84 ABCG2 (0.40) ABCG2ALDH1A1KDM4EMAPTHPGD
SCHEMBL31161080 0.76 GPR139 (0.46) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL31160981 0.75 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTHPGDKMT2A
SCHEMBL31160877 0.75 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTHPGDKMT2A
SCHEMBL2070119 0.75 ABCG2 (0.53) ABCG2ALDH1A1KDM4EMAPTHPGD
SCHEMBL642042 0.69 POLB (0.51) KMT2APOLBDAOMEN1L3MBTL1
SCHEMBL10750340 0.68 PDE3B (0.39) ABCG2ALDH1A1KDM4EMAPTHPGD
SCHEMBL31160837 0.68 FEN1 (0.57) KMT2ADAOMEN1FEN1
SCHEMBL1260385 0.68 ABCG2 (0.45) ABCG2ALDH1A1KDM4EMAPTHPGD
SCHEMBL10085100 0.67 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
EP-4688756-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206345-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 ABCG2 164/4885ALDH1A1 1640/4885KDM4E 2997/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 ABCG2 358/4885ALDH1A1 1070/4885KDM4E 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback